General
Preferred name
EDOXABAN
Synonyms
Lixiana ()
DU-176b ()
DU-176b tosylate Monohydrate ()
Edoxaban Tosylate Monohydrate ()
Edoxaban (tosylate monohydrate) ()
EDOXABAN TOSYLATE ()
Edoxaban (tosylate) ()
Edoxaban tosilate ()
DU-176 ()
DU-176b (monohydrate) ()
DU-176b, Savaysa ()
Savaysa ()
Edoxaban-d6 ()
P&D ID
PD009142
CAS
912273-65-5
1229194-11-9
480449-70-5
480449-71-6
1304701-57-2
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2015
2011
Drug Status
approved
Drug indication
Atrial fibrillation
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
DESCRIPTION Edoxaban is an oral, once-daily factor Xa inhibitor anticoagulant.
Marketed formulations contain edoxaban tosylate (PubChem CID 44610678). (GtoPdb)
Compound Sets
23
AdooQ Bioactive Compound Library
A14317
A18015
Axon Medchem Screening Library
3116
Cayman Chemical Bioactives
24030
25760
ChEMBL Approved Drugs
CHEMBL1269025
CHEMBL2105682
ChEMBL Drugs
CHEMBL1269025
CHEMBL2105682
Concise Guide to Pharmacology 2017/18
7575
Concise Guide to Pharmacology 2019/20
7575
Concise Guide to Pharmacology 2021/22
7575
Drug Repurposing Hub
DrugBank
DB09075
DrugBank Approved Drugs
DB09075
DrugCentral
4897
DrugCentral Approved Drugs
4897
DrugMAP
DMCIJBH
DrugMAP Approved Drugs
DMCIJBH
EU-OPENSCREEN Bioactive Compound Library
EOS101162
Guide to Pharmacology
7575
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1269025
MedChem Express Bioactive Compound Library
HY-10264B
HY-10264
HY-10264A
NCATS Inxight Approved Drugs
NDU3J18APO
ReFrame library
Selleckchem Bioactive Compound Library
edoxaban
edoxaban-du-176b
TargetMol Bioactive Compound Library
T2368
T2368L
External IDs
66
Properties
(calculated by RDKit )
Molecular Weight
547.18
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
2
cLogP
1.29
TPSA
136.63
Fraction CSP3
0.5
Chiral centers
3.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Proteases/Proteasome
Metabolic Enzyme/Protease
Target
Factor Xa
Thrombin
F10
Factor Xa inhibitor
Disease Area
neurology/psychiatry, hematology, cardiology
Indication
stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)
MOA
coagulation factor inhibitor
Source data